Eric Carter Bartee

Title
InstitutionMedical University of South Carolina
DepartmentMicrobiology and Immunology
AddressP.O. Box MSC 504
203
173 Ashley Ave.
Phone843-792-7522
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Dr. Bartee's research interests involve the study of virus-host interactions with particular focus on how these interactions can be used to improve therapy for cancer patients. He is interested in the study of a rabbit-specific poxvirus called myxoma virus and how it interacts with normal and cancerous hematopoietic cells. He is currently exploring whether the virus can be used as a frontline therapy to improve treatment of myeloma patients by directly identifying and eliminating myeloma in vivo, eliminating residual myeloma after chemotherapy or expelling myeloma from its protected bone marrow niches.
    Collapse keywords
    Molecular Virology, Oncolytic Virotherapy

    Collapse ORNG Applications 
    Collapse studies/trials

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Valenzuela-Cardenas M, Gowan C, Dryja P, Bartee MY, Bartee E. TNF blockade enhances the efficacy of myxoma virus-based oncolytic virotherapy. J Immunother Cancer. 2022 05; 10(5). PMID: 35577502.
      Citations:    
    2. Thomas RJ, Bartee E. The use of oncolytic virotherapy in the neoadjuvant setting. J Immunother Cancer. 2022 04; 10(4). PMID: 35414592.
      Citations:    
    3. Smith AS, Knochelmann HM, Wyatt MM, Rangel Rivera GO, Rivera-Reyes AM, Dwyer CJ, Ware MB, Cole AC, Neskey DM, Rubinstein MP, Liu B, Thaxton JE, Bartee E, Paulos CM. B cells imprint adoptively transferred CD8+ T cells with enhanced tumor immunity. J Immunother Cancer. 2022 01; 10(1). PMID: 35017148.
      Citations:    
    4. Dryja P, Fisher C, Woster PM, Bartee E. Inhibition of Polyamine Biosynthesis Using Difluoromethylornithine Acts as a Potent Immune Modulator and Displays Therapeutic Synergy With PD-1-blockade. J Immunother. 2021 10 01; 44(8):283-291. PMID: 34133404.
      Citations:    
    5. Bastian D, Sui X, Nguyen HD, Wu Y, Schutt S, Tian L, Sofi MH, Liu Y, Martin P, Bartee E, Yu XZ. Interleukin-23 receptor signaling by interleukin-39 potentiates T cell pathogenicity in acute graft-versus-host disease. Am J Transplant. 2021 11; 21(11):3538-3549. PMID: 33934505.
      Citations:    
    6. Flores EB, Bartee E. Decreasing the Susceptibility of Malignant Cells to Infection Does Not Impact the Overall Efficacy of Myxoma Virus-Based Oncolytic Virotherapy. Mol Ther Oncolytics. 2020 Dec 16; 19:323-331. PMID: 33335977.
      Citations:    
    7. Flores EB, Aksoy BA, Bartee E. Initial dose of oncolytic myxoma virus programs durable antitumor immunity independent of in vivo viral replication. J Immunother Cancer. 2020 06; 8(1). PMID: 32581062.
      Citations:    
    8. Flores EB, Bartee MY, Bartee E. Reduced cellular binding affinity has profoundly different impacts on the spread of distinct poxviruses. PLoS One. 2020; 15(4):e0231977. PMID: 32352982.
      Citations:    
    9. Burton C, Bartee MY, Bartee E. Impact of Induced Syncytia Formation on the Oncolytic Potential of Myxoma Virus. Oncolytic Virother. 2019; 8:57-69. PMID: 31850282.
      Citations:    
    10. Burton C, Bartee E. Syncytia Formation in Oncolytic Virotherapy. Mol Ther Oncolytics. 2019 Dec 20; 15:131-139. PMID: 31890866.
      Citations:    
    11. Dwyer CJ, Knochelmann HM, Smith AS, Wyatt MM, Rangel Rivera GO, Arhontoulis DC, Bartee E, Li Z, Rubinstein MP, Paulos CM. Fueling Cancer Immunotherapy With Common Gamma Chain Cytokines. Front Immunol. 2019; 10:263. PMID: 30842774.
      Citations:    
    12. Bartee MY, Dryja PC, Bartee E. Chimeric tumor modeling reveals role of partial PDL1 expression in resistance to virally induced immunotherapy. J Immunother Cancer. 2019 01 16; 7(1):11. PMID: 30651147.
      Citations:    
    13. Burton C, Das A, McDonald D, Vandergrift WA, Patel SJ, Cachia D, Bartee E. Oncolytic myxoma virus synergizes with standard of care for treatment of glioblastoma multiforme. Oncolytic Virother. 2018; 7:107-116. PMID: 30538967.
      Citations:    
    14. Wolfe AM, Rahman M, McFadden DG, Bartee EC. Refinement and Successful Implementation of a Scoring System for Myxomatosis in a Susceptible Rabbit (Oryctolagus cuniculus) Model. Comp Med. 2018 08 01; 68(4):280-285. PMID: 30017020.
      Citations:    
    15. Wolfe AM, Dunlap KM, Smith AC, Bartee MY, Bartee E. Myxoma Virus M083 Is a Virulence Factor Which Mediates Systemic Dissemination. J Virol. 2018 04 01; 92(7). PMID: 29343569.
      Citations:    
    16. Bartee E. Potential of oncolytic viruses in the treatment of multiple myeloma. Oncolytic Virother. 2017; 7:1-12. PMID: 29503813.
      Citations:    
    17. Bartee E, Li Z. In vivo and in situ programming of tumor immunity by combining oncolytics and PD-1 immune checkpoint blockade. Exp Hematol Oncol. 2017; 6:15. PMID: 28546884.
      Citations:    
    18. Bartee MY, Dunlap KM, Bartee E. Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy. Cancer Res. 2017 06 01; 77(11):2952-2963. PMID: 28314785.
      Citations:    
    19. Bartee E, Bartee MY, Bogen B, Yu XZ. Systemic therapy with oncolytic myxoma virus cures established residual multiple myeloma in mice. Mol Ther Oncolytics. 2016; 3:16032. PMID: 27933316.
      Citations:    
    20. Bartee MY, Dunlap KM, Bartee E. Myxoma Virus Induces Ligand Independent Extrinsic Apoptosis in Human Myeloma Cells. Clin Lymphoma Myeloma Leuk. 2016 Apr; 16(4):203-12. PMID: 26803534.
      Citations:    
    21. Dunlap KM, Bartee MY, Bartee E. Myxoma virus attenuates expression of activating transcription factor 4 (ATF4) which has implications for the treatment of proteasome inhibitor-resistant multiple myeloma. Oncolytic Virother. 2015; 4:1-11. PMID: 27512665.
      Citations:    
    22. Bartee E, McFadden G. Cytokine synergy: an underappreciated contributor to innate anti-viral immunity. Cytokine. 2013 Sep; 63(3):237-40. PMID: 23693158.
      Citations:    
    23. Chan WM, Bartee EC, Moreb JS, Dower K, Connor JH, McFadden G. Myxoma and vaccinia viruses bind differentially to human leukocytes. J Virol. 2013 Apr; 87(8):4445-60. PMID: 23388707.
      Citations:    
    24. Bartee E, Meacham A, Wise E, Cogle CR, McFadden G. Virotherapy using myxoma virus prevents lethal graft-versus-host disease following xeno-transplantation with primary human hematopoietic stem cells. PLoS One. 2012; 7(8):e43298. PMID: 22905251.
      Citations:    
    25. Bartee E, Chan WM, Moreb JS, Cogle CR, McFadden G. Selective purging of human multiple myeloma cells from autologous stem cell transplantation grafts using oncolytic myxoma virus. Biol Blood Marrow Transplant. 2012 Oct; 18(10):1540-51. PMID: 22516053.
      Citations:    
    26. Madlambayan GJ, Bartee E, Kim M, Rahman MM, Meacham A, Scott EW, McFadden G, Cogle CR. Acute myeloid leukemia targeting by myxoma virus in vivo depends on cell binding but not permissiveness to infection in vitro. Leuk Res. 2012 May; 36(5):619-24. PMID: 22341701.
      Citations:    
    27. Bais S, Bartee E, Rahman MM, McFadden G, Cogle CR. Oncolytic virotherapy for hematological malignancies. Adv Virol. 2012; 2012:186512. PMID: 22312362.
      Citations:    
    28. Bartee E, Eyster CA, Viswanathan K, Mansouri M, Donaldson JG, Früh K. Membrane-Associated RING-CH proteins associate with Bap31 and target CD81 and CD44 to lysosomes. PLoS One. 2010 Dec 02; 5(12):e15132. PMID: 21151997.
      Citations:    
    29. Villa NY, Bartee E, Mohamed MR, Rahman MM, Barrett JW, McFadden G. Myxoma and vaccinia viruses exploit different mechanisms to enter and infect human cancer cells. Virology. 2010 Jun 05; 401(2):266-79. PMID: 20334889.
      Citations:    
    30. McFadden G, Mohamed MR, Rahman MM, Bartee E. Cytokine determinants of viral tropism. Nat Rev Immunol. 2009 Sep; 9(9):645-55. PMID: 19696766.
      Citations:    
    31. Bartee E, McFadden G. Human cancer cells have specifically lost the ability to induce the synergistic state caused by tumor necrosis factor plus interferon-beta. Cytokine. 2009 Sep; 47(3):199-205. PMID: 19640730.
      Citations:    
    32. Bartee E, Mohamed MR, Lopez MC, Baker HV, McFadden G. The addition of tumor necrosis factor plus beta interferon induces a novel synergistic antiviral state against poxviruses in primary human fibroblasts. J Virol. 2009 Jan; 83(2):498-511. PMID: 18971273.
      Citations:    
    33. Wang F, Gao X, Barrett JW, Shao Q, Bartee E, Mohamed MR, Rahman M, Werden S, Irvine T, Cao J, Dekaban GA, McFadden G. RIG-I mediates the co-induction of tumor necrosis factor and type I interferon elicited by myxoma virus in primary human macrophages. PLoS Pathog. 2008 Jul 11; 4(7):e1000099. PMID: 18617992.
      Citations:    
    34. Bartee E, Mohamed MR, McFadden G. Tumor necrosis factor and interferon: cytokines in harmony. Curr Opin Microbiol. 2008 Aug; 11(4):378-83. PMID: 18595771.
      Citations:    
    35. Thibodeau J, Bourgeois-Daigneault MC, Huppé G, Tremblay J, Aumont A, Houde M, Bartee E, Brunet A, Gauvreau ME, de Gassart A, Gatti E, Baril M, Cloutier M, Bontron S, Früh K, Lamarre D, Steimle V. Interleukin-10-induced MARCH1 mediates intracellular sequestration of MHC class II in monocytes. Eur J Immunol. 2008 May; 38(5):1225-30. PMID: 18389477.
      Citations:    
    36. Bartee E, McCormack A, Früh K. Quantitative membrane proteomics reveals new cellular targets of viral immune modulators. PLoS Pathog. 2006 Oct; 2(10):e107. PMID: 17238276.
      Citations:    
    37. Hassink G, Kikkert M, van Voorden S, Lee SJ, Spaapen R, van Laar T, Coleman CS, Bartee E, Früh K, Chau V, Wiertz E. TEB4 is a C4HC3 RING finger-containing ubiquitin ligase of the endoplasmic reticulum. Biochem J. 2005 Jun 01; 388(Pt 2):647-55. PMID: 15673284.
      Citations:    
    38. Nerenberg BT, Taylor J, Bartee E, Gouveia K, Barry M, Früh K. The poxviral RING protein p28 is a ubiquitin ligase that targets ubiquitin to viral replication factories. J Virol. 2005 Jan; 79(1):597-601. PMID: 15596852.
      Citations:    
    39. Bartee E, Mansouri M, Hovey Nerenberg BT, Gouveia K, Früh K. Downregulation of major histocompatibility complex class I by human ubiquitin ligases related to viral immune evasion proteins. J Virol. 2004 Feb; 78(3):1109-20. PMID: 14722266.
      Citations:    
    40. Mansouri M, Bartee E, Gouveia K, Hovey Nerenberg BT, Barrett J, Thomas L, Thomas G, McFadden G, Früh K. The PHD/LAP-domain protein M153R of myxomavirus is a ubiquitin ligase that induces the rapid internalization and lysosomal destruction of CD4. J Virol. 2003 Jan; 77(2):1427-40. PMID: 12502858.
      Citations:    
    41. Früh K, Bartee E, Gouveia K, Mansouri M. Immune evasion by a novel family of viral PHD/LAP-finger proteins of gamma-2 herpesviruses and poxviruses. Virus Res. 2002 Sep; 88(1-2):55-69. PMID: 12297327.
      Citations:    
    Bartee's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (180)
    Explore
    _
    Co-Authors (17)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _